Intrexon | XON - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agenus USD 14.4M 19.26M 2025-12
Alaunos Therapeutics USD -1.01M 175K 2026-03
Amgen USD 3.83B 130M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -141.26M 182.07M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Incyte USD 324.17M 59.7M 2026-03
Intrexon USD -60.84M 26.62M 2024-06
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Ligand Pharmaceuticals USD 60.33M 40.29M 2026-03
MacroGenics USD -33.44M 21.34M 2026-03
MannKind USD -76.99M 7.75M 2026-03
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.24B 171M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Thermo Fisher Scientific USD 1.91B 389M 2026-03
Veracyte USD 19.08M 5.55M 2026-03
Xencor USD -77.86M 24.23M 2026-03